# Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

> **NCT02795884** · PHASE3 · WITHDRAWN · sponsor: **Yonsei University**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** intercalation therapy using pemetrexed, cisplatin and erlotinib
- **DRUG:** Vinorelbine, cisplatin

## Key facts

- **NCT ID:** NCT02795884
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim
- **Last updated:** 2016-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795884, "Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02795884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*